Ailani J, Lipton RB, Goadsby PJ, et al. - Reduction in the number of migraine days and headache days was observed over a period of 12 weeks when atogepant, an oral, small-molecule, calcitonin gene–related peptide receptor antagonist, was provided once daily to adults with 4 to 14 migraine days per month.

• In this phase 3, double-blind trial, participants were administered either once-daily dose of oral atogepant (10 mg, 30 mg, or 60 mg) or placebo for 12 weeks.

• From baseline across 12 weeks, the following changes were recorded: −3.7 days with 10-mg atogepant, −3.9 days with 30-mg atogepant, −4.2 days with 60-mg atogepant, and −2.5 days with placebo.

• Constipation and nausea were described as the most common adverse events.